Rasburicase in cancer-related hyperuricemia

Drugs of Today

Volumn 47, Issue 8, 2011, Pages 591-603

  Rodriguez, M ^a   Campara, M ^a   Haaf, Christina ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLANTOIN; ALLOPURINOL; ANTINEOPLASTIC AGENT; AZATHIOPRINE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; MERCAPTOPURINE; PURINE; RASBURICASE; URIC ACID; URICOZYME; XANTHINE; XANTHINE OXIDASE;

ALKALINIZATION; ANAPHYLAXIS; ANOREXIA; BRONCHOSPASM; CANCER CELL; CANCER CHEMOTHERAPY; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE CLASSIFICATION; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FLUID THERAPY; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; GROUPS BY AGE; HEART ARRHYTHMIA; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN; HYPERURICEMIA; HYPOCALCEMIA; HYPOTENSION; HYPOXEMIA; IMMUNOGENICITY; KIDNEY FAILURE; LABORATORY TEST; METHEMOGLOBINEMIA; MULTICENTER STUDY (TOPIC); MUSCLE CRAMP; NAUSEA; NONHUMAN; OPTIMAL DRUG DOSE; PARESTHESIA; PRACTICE GUIDELINE; PURINE METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SIDE EFFECT; TETANY; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL;

ALLOPURINOL; HUMANS; HYPERURICEMIA; TUMOR LYSIS SYNDROME; URATE OXIDASE;

EID: 80052782576     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2011.47.8.1622067     Document Type: Review

References (40)

1. Mughal, T., Ahsan Ejaz, A., Foringer J. et al. An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome. Cancer Treat Rev 2010, 36(2): 164-76.
2. Hochberg, J., Cairo, M.S, Coccia, P.F. Tumor lysis syndrome. In: Abeloff's Clinical Oncology, 4th Ed. M. Abeloff, J. Armitage (Eds.). Churchill Livingston: Philadelphia 2008, 759-65.
3. Gucalp, R., Dutcher, J.P. Oncologic emergencies. In: Harrison's Principles of Internal Medicine, 14th Ed. A.S. Fauci, E. Braunwald, D.L. Kasper, S.L., Hauser, D.L., Longo, J.L. Jameson, J. Loscalzo (Eds.). McGraw-Hill: New York 1998, 627-34.
4. Kennedy, L., Ajiboye, V. Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome. J Oncol Pharm Pract 2010, 16(3): 205-13.
5. Coiffier, B., Altman, A., Pui, C.H. et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: An evidence-based review. J Clin Oncol 2008, 26(16): 2767-78.
6. Sood, A., Burry, L., Cheng, D. Clarifying the role of rasburicase in tumor lysis syndrome. Pharmacotherapy 2007, 27(1): 111-21.
7. National Institutes of Health. National Cancer Institute. Common toxicity Criteria version 2. April 30, 1999. Accessed November 13, 2010.
8. National Institutes of Health. National Cancer Institute. Common toxicity Criteria for Adverse Events. Version 4.3. June 14, 2010. Accessed November 13, 2010.
9. Hande, K.R., Garrow, G.C. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 1993, 94(2): 133-9.
10. Pession, A., Melchionda, F., Castellini, C. Pitfalls, prevention and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase). Biologics 2008, 2(1): 129-41.
11. Allopurinol [package insert]. Greenville, NC: Prometheus Laboratories Inc; 2003.
12. Yim, B., Sims-McCallum, R.P., Chong, P. Rasburicase for the treatment and prevention of hyperuricemia. Ann Pharmacother 2003, 37(7-8): 1047-54.
13. Mahamoud, H.H., Leverger, G., Harvey, E. et al. Advances in the management of malignancy-associated hyperuricemia. Br J Cancer 1998, 77(Suppl. 4): 18-20.
14. Oldfield, V., Perry, C. Rasburicase: A review of its use in the management of anticancer therapy-induced hyperuricemia. Drugs 2006, 66(4): 529-45.
15. Goldman, S., Holcenberg, J., Finklestein, J. et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001, 97(10): 2998-3003.
16. Elitek Prescribing Information. http://products.sanofiaventis. us/elitek/elitek.html. Accessed August 29, 2010.
17. Lascombes, F., Sommelet, D., Gebhard, F. et al. High efficacy of recombinant urate oxidase in prevention of renal failure related to tumor lysis syndrome (TLS). Blood 1998, 92(Suppl. 1): Abst 4019.
18. Pui, C.H., Hazem, M., Wiley, J. et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001, 19(3): 697-704.
19. Cortes, J., O'Moore, J., Maziarz, R. et al. Control of plasma uric acid in adults at risk for tumor lysis syndrome: Efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone - Results of a multicenter phase III study. J Clin Oncol 2010, 28(27): 4207-13.
20. Kikuchi, A., Kigasawa, H., Tsurusawa, M. et al. A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome. Int J Hematol 2009, 90(4): 492-500.
21. Bosly, A., Sonet, A., Pinkerton, R. et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: Report of an international compassionate use study. Cancer 2003, 98(5): 1048-54.
22. Wang, L.Y., Shih, LY., Chang, H. et al. Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies. Acta Haematol 2006, 115(1-2): 35-8.
23. Shin, H.Y., Kang, H.J., Park, E.S. et al. Recombinant urate oxidase (rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: Results of a compassionate prospective multicenter study in Korea. Pediatr Blood Cancer 2006, 46(4): 439-45.
24. Renyi, I., Bardi, E., Udvardi, E. et al. Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma. Pathol Oncol Res 2007, 13(1): 58-63.
25. Jeha, S., Kantarjian, H., Irwin, D. et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: Final results of a multicenter compassionate use trial. Leukemia 2005, 19(1): 34-8.
26. Coiffier, B., Mounier, N., Bologna, S. et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkins lymphoma: Results of the GRAAL1 (groupe d'etude des lymphomes de l'adulte trial on rasburicase activity in adult lymphoma) study. J Clin Oncol 2003, 21(23): 4402-6.
27. Liu, C., Sims-McCallum, R., Schiffer, C. A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy. Leuk Res 2005, 29(4): 463-5.
28. Campara, M., Shord, S., Haaf, C. Single dose rasburicase for tumor lysis syndrome in adults: Weight based approach. J Clin Pharm Ther 2009, 34(2): 207-13.
29. Reeves, D., Bestul, D. Evaluation of a single dose of rasburicase 7.5 mg for the treatment of hyperuricemia in adults with cancer. Pharmacotherapy 2008, 28(6): 685-90.
30. Knoebel, R., Lo, M., Crank, C. Evaluation of a low, weightbased dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome. J Oncol Pharm Pract 2010, Advance publication.
31. Vines, A., Shanholtz, C., Thompson, J. et al. Fixed dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients. Ann Pharmacother 2010, 44(10): 1529-37.
32. Hutcherson, D., Gammon, B.S., Bhatt, M., Faneuf, M. Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. Pharmacotherapy 2006, 26(2): 242-7.
33. McDonnell, A., Lenz, K., Frei-Lahr, D. et al. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults. Pharmacotherapy 2006, 26(6): 806-12.
34. Trifilio, S., Gordon, L., Singhal, S. et al. Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplant 2006, 37(11): 997-1001.
35. Trifilio, S., Pi, J., Zook, J. et al. Effectiveness of a single 3 mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies. Bone Marrow Transplant 2011, 46(6): 800-5.
36. Kizer, N., Martinez, E., Powell, M. Report of two cases of rasburicase- induced methemoglobinemia. Leuk Lymphoma 2006, 47(12): 2648-50.
37. Borinstein, S.C., Xu, M., Hawkins, D.S. Methemoglobinemia and hemolytic anemia caused by rasburicase administration in a newly diagnosed child with Burkitt lymphoma/ leukemia. Pediatr Blood Cancer 2008, 50(1): 189.
38. Browning, L., Kruse, J. Hemolysis and methemoglobinemia secondary to rasburicase administration. Ann Pharmacother 2005, 39(11): 1932-5.
39. Annemans, L., Moeremans, K., Lamotte, M. et al. Pan- European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricemia and tumour lysis syndrome in haematological cancer patients. Support Care Center 2003, 11(4): 249-57.
40. Drug Topics Red Book. Montvale, NJ: Thomson Healthcare; 401.